<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Treatment efficacy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/treatment-efficacy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 20 Jan 2026 09:33:12 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Treatment efficacy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Comparative Analysis of Treatments for Severe Crohn’s Disease</title>
		<link>https://bioengineer.org/comparative-analysis-of-treatments-for-severe-crohns-disease/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 09:32:44 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Biologic Therapies]]></category>
		<category><![CDATA[Biologics Comparative Efficacy]]></category>
		<category><![CDATA[Crohn's Disease Advanced Therapies]]></category>
		<category><![CDATA[IL-12/23 inhibitörleri]]></category>
		<category><![CDATA[integr]]></category>
		<category><![CDATA[Maintenance Treatment]]></category>
		<category><![CDATA[Makale içeriğine göre en uygun 5 etiket: **Crohn's Disease Treatments]]></category>
		<category><![CDATA[Moderate-to-Severe Crohn's]]></category>
		<category><![CDATA[Network Meta-Analysis]]></category>
		<category><![CDATA[Patient Safety** * **Gerekçeler:** * **Crohn's Disease Treatments:** Makalenin ana konusu. * **Biologic Therapies:** İçerikte özellikle anti-TNF]]></category>
		<category><![CDATA[Treatment efficacy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/comparative-analysis-of-treatments-for-severe-crohns-disease/</guid>

					<description><![CDATA[In the realm of gastroenterology, Crohn’s disease has emerged as a significant health burden, affecting millions worldwide. Characterized by chronic inflammation of the gastrointestinal tract, this condition not only disrupts digestive health but also severely impacts the quality of life of patients. The complex pathogenesis of Crohn’s disease indicates a multifactorial etiology, involving genetic predispositions, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318821</post-id>	</item>
		<item>
		<title>Ponatinib in CML: Insights from the PONDEROSA Study</title>
		<link>https://bioengineer.org/ponatinib-in-cml-insights-from-the-ponderosa-study/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 18 Jan 2026 21:56:50 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Chronic Myeloid Leukemia]]></category>
		<category><![CDATA[Makale içeriğine uygun 5 etiket: **Chronic myeloid leukemia]]></category>
		<category><![CDATA[Ponatinib]]></category>
		<category><![CDATA[PONDEROSA study]]></category>
		<category><![CDATA[Real-world data]]></category>
		<category><![CDATA[Treatment efficacy]]></category>
		<category><![CDATA[Treatment efficacy** **Açıklama:** 1. **Chronic myeloid leukemia (CML):** Makalenin temel konusu olan hastalık. 2. **Ponatinib:** Makalenin ve çalışmanın odak noktası olan ilaç/]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ponatinib-in-cml-insights-from-the-ponderosa-study/</guid>

					<description><![CDATA[In the ever-evolving landscape of cancer treatment, chronic myeloid leukemia (CML) is a challenging adversary. As oncologists and clinical researchers strive to improve patient outcomes, developments in therapies such as Ponatinib have ignited both excitement and skepticism within the medical community. A recent study, known as PONDEROSA, explores the efficacy of Ponatinib in CML patients [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318051</post-id>	</item>
	</channel>
</rss>
